Unknown

Dataset Information

0

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.


ABSTRACT: INTRODUCTION:Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer. NY-ESO-1, a cancer testis antigen is the most immunogenic antigen to date. The promise of NY-ESO-1 as a candidate for specific immune recognition of cancer comes from its restricted expression in normal adult tissue but frequent occurrence in multiple tumors including melanoma and carcinomas of lung, esophageal, liver, gastric, prostrate, ovarian, and bladder. MAIN BODY:This review summarizes current knowledge of NY-ESO-1 as efficient biomarker and target of immunotherapy. It also addresses limitations and challenges preventing a robust immune response to NY-ESO-1 expressing cancers, and describes pre-clinical and clinical observations relevant to NY-ESO-1 immunity, holding potential therapeutic relevance for cancer treatment. CONCLUSION:NY-ESO-1 induces strong immune responses in cancer patients but has limited objective clinical responses to NY-ESO-1 expressing tumors due to effect of competitive negative signaling from immune-checkpoints and immune-suppressive tumor microenvironment. We propose that combination therapy to increase the efficacy of NY-ESO-1 specific immunotherapeutic interventions should be explored to unleash the immune response against NY-ESO-1 expressing tumors.

SUBMITTER: Raza A 

PROVIDER: S-EPMC7102435 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.

Raza Afsheen A   Merhi Maysaloun M   Inchakalody Varghese Philipose VP   Krishnankutty Roopesh R   Relecom Allan A   Uddin Shahab S   Dermime Said S  

Journal of translational medicine 20200327 1


<h4>Introduction</h4>Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer. NY-ESO-1, a cancer testis antigen is the most immunogenic antigen to date. The promise of NY-ESO-1 as a candidate for specific immune recognition of cancer comes from its restricted expression  ...[more]

Similar Datasets

| S-EPMC5941317 | biostudies-literature
| S-EPMC8340627 | biostudies-literature
| S-EPMC3117860 | biostudies-literature
| S-EPMC4170640 | biostudies-literature
| S-EPMC5512893 | biostudies-other
| S-EPMC1570182 | biostudies-literature
| S-EPMC4100683 | biostudies-literature
| S-EPMC4928360 | biostudies-literature
| S-EPMC3361576 | biostudies-literature
| S-EPMC8581324 | biostudies-literature